Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
PRME · Why this verdict
Why Prime Medicine (PRME) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
PRME shows a high-asymmetry technical recovery with large modeled upside, but extreme cash burn keeps quality well below an acceptable floor, and elevated options positioning alongside thin analyst coverage adds further uncertainty to the setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
PRME shows a high asymmetry ratio of 3.85 with roughly 58% modeled upside, in a recovery setup where MACD is improving despite a prior death cross and an RSI reading of 79. Reward-to-risk math | The recovery should continue, with price advancing toward the analyst-implied take-profit level over the next 12 months. | →Stable |
| CounterThe RSI reading of 79 reflects an overbought bear-market rally, and the underlying quality score is weak, suggesting the recovery lacks fundamental support. | ||
PRME's quality score sits below an acceptable floor, driven by extreme cash burn near -1941% of revenue and a weak Piotroski F-Score of 2 out of 9. Quality breakdown | Cash burn as a percentage of revenue should narrow substantially, and the Piotroski F-Score should rise, if quality concerns ease over the next 12 months. | →Stable |
| CounterExtreme negative cash-flow-to-revenue ratios are common and expected for pre-revenue clinical-stage gene-editing companies, where research spend vastly exceeds any near-term product revenue. | ||
Analyst price targets imply roughly 81% upside for PRME, though the underlying analyst coverage is described as light, dampening confidence in the signal. Sentiment breakdown | Analyst coverage should broaden and price targets should hold or increase over the next 12 months. | ↑Improving |
| CounterLight coverage means the large upside figure rests on a small sample of estimates and could be skewed by one or two outlier price targets. | ||
PRME options carry an elevated put/call ratio near 2.91 and high implied volatility near 107%, alongside 23% short interest. Risk breakdown | Implied volatility should compress from roughly 107% and the put/call ratio should normalize toward 1.0 over the next 12 months. | ↑Improving |
| CounterThe elevated short interest is separately characterized as justified, suggesting the bearish options positioning reflects informed skepticism rather than a mispricing likely to reverse. | ||
PRME shows a high asymmetry ratio of 3.85 with roughly 58% modeled upside, in a recovery setup where MACD is improving despite a prior death cross and an RSI reading of 79.
→StableReward-to-risk math
- Expectation
- The recovery should continue, with price advancing toward the analyst-implied take-profit level over the next 12 months.
CounterThe RSI reading of 79 reflects an overbought bear-market rally, and the underlying quality score is weak, suggesting the recovery lacks fundamental support.
PRME's quality score sits below an acceptable floor, driven by extreme cash burn near -1941% of revenue and a weak Piotroski F-Score of 2 out of 9.
→StableQuality breakdown
- Expectation
- Cash burn as a percentage of revenue should narrow substantially, and the Piotroski F-Score should rise, if quality concerns ease over the next 12 months.
CounterExtreme negative cash-flow-to-revenue ratios are common and expected for pre-revenue clinical-stage gene-editing companies, where research spend vastly exceeds any near-term product revenue.
Analyst price targets imply roughly 81% upside for PRME, though the underlying analyst coverage is described as light, dampening confidence in the signal.
↑ImprovingSentiment breakdown
- Expectation
- Analyst coverage should broaden and price targets should hold or increase over the next 12 months.
CounterLight coverage means the large upside figure rests on a small sample of estimates and could be skewed by one or two outlier price targets.
PRME options carry an elevated put/call ratio near 2.91 and high implied volatility near 107%, alongside 23% short interest.
↑ImprovingRisk breakdown
- Expectation
- Implied volatility should compress from roughly 107% and the put/call ratio should normalize toward 1.0 over the next 12 months.
CounterThe elevated short interest is separately characterized as justified, suggesting the bearish options positioning reflects informed skepticism rather than a mispricing likely to reverse.
Per-dimension breakdown
Quality
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.2 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -1941% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
0.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
- ▸Declining revenue: -41%
Momentum
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 1.8 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 0.5 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -4.0%/30d — confirmed downtrend
Sentiment
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 7.0 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.70 (n=1)
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 140%
Insider
6.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 7.2 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
1.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 1.9 |
Technical
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.4 |
| support resistance | 9.8 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.0 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 2.4 |
| debt equity | 4.0 |
| news risk | 5.5 |
- ▸High short interest justified: 25%
- ▸Elevated put/call: 2.50
- ▸High IV: 87%
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/3M
- ▸Earnings in 12 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (4)
- ASYMMETRY:7.2>=1.5
- INSIDER:OK
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:1.6<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:12d<=14d (soft)
Reward-to-Risk
7.23
Upside
+108.5%
Downside
15.0%
Sizing output
AVOID
SetupFalling Knife — Death cross, below all MAs, RSI 33, MACD bearish
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Drawdown -57% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 1.6<4.5 outcome against Value at 9.0 and asymmetric R:R of 7.23.
The strongest dimensions are Value at 9.0, Sentiment at 8.4, and Insider at 6.4; the weakest are Growth at 0.0, Risk (lower is worse) at 1.6, and Momentum at 1.6. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 7.23 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Asymmetry Recovery Setup
Trip ifAsymmetry ratio falls below 1.5, causing the recovery setup to no longer clear the asymmetry threshold.
- P2Extreme Cash Burn Quality Concern
Trip ifPiotroski F-Score rises above 4 out of 9 from the current 2, and cash burn improves above -500% of revenue, showing quality concerns have eased.
- P3Analyst Upside With Light Coverage
Trip ifAnalyst price target is cut more than 20% from current levels, undermining the upside case.
- P4Elevated Put Call And Implied Volatility
Trip ifImplied volatility falls below 60% from the current 107%, showing the elevated volatility risk has resolved.